Lab Lowdown for October 23, 2026

This week’s Lab Lowdown covers verified announcements published from Oct. 17 through the Friday morning research cutoff on Oct. 23, 2026. The strongest developments span preclinical regulatory science, environmental monitoring, decentralized diagnostics, sequencing economics, biomedical data infrastructure, and European cancer screening.

The through line is operational: new tools are moving from isolated technical improvements toward connected workflows that laboratories will have to validate, govern, and scale.

FDA Collaboration Targets Preclinical Abuse-Potential Testing

On Oct. 22, Labcorp, Charles River Laboratories, and the U.S. Food and Drug Administration announced a research collaboration to advance preclinical methods for evaluating the abuse potential of medicines. The project will examine behavioral-economics approaches intended to quantify and rank how strongly test subjects prefer a drug over an alternative. The collaborators describe the work as method development, rather than a newly validated test or commercial service.

For pharmaceutical and contract research laboratories, the practical issue is comparability. Better-harmonized designs could make nonclinical evidence more consistent across programs and help teams identify abuse-liability signals earlier. Implementation details, validation results, and regulatory use still have to emerge. Read the LabPress report.

Vaisala Moves GxP Environmental Monitoring to the Cloud

Vaisala introduced ViewLinc Cloud Suite on Oct. 22. The offering includes a professional configuration for laboratory monitoring and a GxP configuration with validation documentation and regulated-workflow support. Vaisala says the platform provides continuous monitoring, alerts, reports, and audit-trail capabilities without an on-site server. Initial availability is planned by the end of 2026 in North America, Europe, the Middle East, and Africa.

The appeal is a single monitoring architecture that can follow a growing laboratory into regulated production. Cloud delivery does not remove qualification work, however. Quality teams still need to assess data integrity, access control, change management, retention, supplier oversight, and business continuity against their own procedures. See the LabPress overview.

At-Home HPV Screening Puts Preanalytics in Focus

Waters Corporation and Quest Diagnostics announced an Oct. 20 collaboration intended to broaden U.S. access to the FDA-cleared Onclarity HPV Self-Collection Kit. The companies plan to make the option available through Quest’s clinician, health-plan, and consumer channels beginning in 2027. The associated assay provides extended HPV genotyping and runs on the BD COR system, now within Waters’ diagnostics portfolio.

For clinical laboratories, wider self-collection changes more than the collection site. Programs must control kit distribution, labeling, transit time, sample stability, accessioning, rejection criteria, result delivery, and follow-up for positive findings. Those preanalytical and postanalytical details will determine whether access gains translate into dependable screening workflows. Read LabPress coverage.

Ultima Adds Paired-End Sequencing as Output Claims Climb

Ultima Genomics announced the commercial launch of paired-end sequencing for its UG200 series and the availability of Solaris 2.0 Max consumables on Oct. 20. The company says the Max configuration can generate as many as 20 billion reads per wafer, double its previous Solaris output, and support a $60 30x human genome. Those throughput and cost figures are vendor estimates, and early-access deployments are still generating practical evidence.

Paired-end reads expand compatibility with established analysis pipelines and applications that benefit from information at both ends of a fragment. Laboratories comparing platforms should look past headline cost per genome to usable yield, accuracy by variant class, sample batching, run cadence, compute demands, service coverage, and total workflow cost. LabPress has the launch details.

PacBio and Verily Pair HiFi Reads With Biomedical AI

PacBio and Verily Health announced a multiyear collaboration on Oct. 19 to connect PacBio HiFi sequencing workflows with the governed data and AI environment in Verily Pre. The companies plan to integrate long-read genomic data with real-world clinical data for population-scale research, including work in Verily Pre Workbench. The announcement describes intended research capabilities, not a clinical device or validated diagnostic system.

The laboratory challenge is increasingly the handoff between instruments, pipelines, identity controls, metadata, and approved research environments. Long reads can capture structural variation, methylation, and full-length transcripts that are harder to resolve with short reads, but their value depends on traceable processing and defensible access governance. Read the LabPress analysis.

Abbott’s Cologuard Plus Receives CE Mark

Abbott said on Oct. 20 that Cologuard Plus received CE Mark under the European Union’s In Vitro Diagnostic Medical Devices Regulation. The stool-based test analyzes DNA markers and occult blood associated with colorectal cancer and advanced precancerous lesions. Abbott reported 95% sensitivity for colorectal cancer at 94% specificity in the prospective BLUE-C study of more than 20,000 participants. Those performance values come from the company’s announcement and published study; real-world results depend on the tested population and program design.

The CE Mark clears an important regulatory step, while country-level availability will still depend on reimbursement, screening pathways, and operational readiness. Laboratories preparing for adoption will need capacity plans for kit logistics, sample processing, confirmatory colonoscopy referrals, quality indicators, and communication across decentralized care pathways. See the LabPress summary.